These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 31577946)

  • 1. Type I Interferon Delivery by iPSC-Derived Myeloid Cells Elicits Antitumor Immunity via XCR1
    Tsuchiya N; Zhang R; Iwama T; Ueda N; Liu T; Tatsumi M; Sasaki Y; Shimoda R; Osako Y; Sawada Y; Kubo Y; Miyashita A; Fukushima S; Cheng Z; Nakaki R; Takubo K; Okada S; Kaneko S; Ihn H; Kaisho T; Nishimura Y; Senju S; Endo I; Nakatsura T; Uemura Y
    Cell Rep; 2019 Oct; 29(1):162-175.e9. PubMed ID: 31577946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of GM-CSF-producing antigen-presenting cells that induce a cytotoxic T cell-mediated antitumor response.
    Mashima H; Zhang R; Kobayashi T; Hagiya Y; Tsukamoto H; Liu T; Iwama T; Yamamoto M; Lin C; Nakatsuka R; Mishima Y; Watanabe N; Yamada T; Senju S; Kaneko S; Idiris A; Nakatsura T; Ohdan H; Uemura Y
    Oncoimmunology; 2020 Sep; 9(1):1814620. PubMed ID: 33457097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Type I interferon-mediated tumor immunity and its role in immunotherapy.
    Yu R; Zhu B; Chen D
    Cell Mol Life Sci; 2022 Mar; 79(3):191. PubMed ID: 35292881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of cDC-like cells from human induced pluripotent stem cells via Notch signaling.
    Makino K; Long MD; Kajihara R; Matsueda S; Oba T; Kanehira K; Liu S; Ito F
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Type I interferons and dendritic cells in cancer immunotherapy.
    Sprooten J; Agostinis P; Garg AD
    Int Rev Cell Mol Biol; 2019; 348():217-262. PubMed ID: 31810554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TIM-3 blockade enhances IL-12-dependent antitumor immunity by promoting CD8
    Gardner A; de Mingo Pulido Á; Hänggi K; Bazargan S; Onimus A; Kasprzak A; Conejo-Garcia JR; Rejniak KA; Ruffell B
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 34987021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Viral infection of cells within the tumor microenvironment mediates antitumor immunotherapy via selective TBK1-IRF3 signaling.
    Brown MC; Mosaheb MM; Mohme M; McKay ZP; Holl EK; Kastan JP; Yang Y; Beasley GM; Hwang ES; Ashley DM; Bigner DD; Nair SK; Gromeier M
    Nat Commun; 2021 Mar; 12(1):1858. PubMed ID: 33767151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Type I IFN Activating Type I Dendritic Cells for Antitumor Immunity.
    Liang Y; Hannan R; Fu YX
    Clin Cancer Res; 2021 Jul; 27(14):3818-3824. PubMed ID: 33692027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intratumoral administration of mRNA encoding a fusokine consisting of IFN-β and the ectodomain of the TGF-β receptor II potentiates antitumor immunity.
    Van der Jeught K; Joe PT; Bialkowski L; Heirman C; Daszkiewicz L; Liechtenstein T; Escors D; Thielemans K; Breckpot K
    Oncotarget; 2014 Oct; 5(20):10100-13. PubMed ID: 25338019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8+ T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells.
    Salem ML; Kadima AN; El-Naggar SA; Rubinstein MP; Chen Y; Gillanders WE; Cole DJ
    J Immunother; 2007 Jan; 30(1):40-53. PubMed ID: 17198082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. STING contributes to antiglioma immunity via triggering type I IFN signals in the tumor microenvironment.
    Ohkuri T; Ghosh A; Kosaka A; Zhu J; Ikeura M; David M; Watkins SC; Sarkar SN; Okada H
    Cancer Immunol Res; 2014 Dec; 2(12):1199-208. PubMed ID: 25300859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced type I interferon signalling promotes Th1-biased inflammation in cutaneous lupus erythematosus.
    Wenzel J; Wörenkämper E; Freutel S; Henze S; Haller O; Bieber T; Tüting T
    J Pathol; 2005 Mar; 205(4):435-42. PubMed ID: 15685590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. STING Activated Tumor-Intrinsic Type I Interferon Signaling Promotes CXCR3 Dependent Antitumor Immunity in Pancreatic Cancer.
    Vonderhaar EP; Barnekow NS; McAllister D; McOlash L; Eid MA; Riese MJ; Tarakanova VL; Johnson BD; Dwinell MB
    Cell Mol Gastroenterol Hepatol; 2021; 12(1):41-58. PubMed ID: 33548597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
    Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
    Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity.
    Burnette BC; Liang H; Lee Y; Chlewicki L; Khodarev NN; Weichselbaum RR; Fu YX; Auh SL
    Cancer Res; 2011 Apr; 71(7):2488-96. PubMed ID: 21300764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Dual Role of Type I Interferons in Antitumor Immunity.
    Zhou L; Zhang Y; Wang Y; Zhang M; Sun W; Dai T; Wang A; Wu X; Zhang S; Wang S; Zhou F
    Adv Biosyst; 2020 Nov; 4(11):e1900237. PubMed ID: 33245214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity.
    Yang SC; Hillinger S; Riedl K; Zhang L; Zhu L; Huang M; Atianzar K; Kuo BY; Gardner B; Batra RK; Strieter RM; Dubinett SM; Sharma S
    Clin Cancer Res; 2004 Apr; 10(8):2891-901. PubMed ID: 15102698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TLR7 ligand augments GM-CSF-initiated antitumor immunity through activation of plasmacytoid dendritic cells.
    Narusawa M; Inoue H; Sakamoto C; Matsumura Y; Takahashi A; Inoue T; Watanabe A; Miyamoto S; Miura Y; Hijikata Y; Tanaka Y; Inoue M; Takayama K; Okazaki T; Hasegawa M; Nakanishi Y; Tani K
    Cancer Immunol Res; 2014 Jun; 2(6):568-80. PubMed ID: 24830413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toll-like receptor 3 agonist complexed with cationic liposome augments vaccine-elicited antitumor immunity by enhancing TLR3-IRF3 signaling and type I interferons in dendritic cells.
    Wang C; Zhuang Y; Zhang Y; Luo Z; Gao N; Li P; Pan H; Cai L; Ma Y
    Vaccine; 2012 Jul; 30(32):4790-9. PubMed ID: 22634298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MAVS-dependent IRF3/7 bypass of interferon β-induction restricts the response to measles infection in CD150Tg mouse bone marrow-derived dendritic cells.
    Takaki H; Honda K; Atarashi K; Kobayashi F; Ebihara T; Oshiumi H; Matsumoto M; Shingai M; Seya T
    Mol Immunol; 2014 Feb; 57(2):100-10. PubMed ID: 24096085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.